Background: The primary function of integrin b 7 is the recruitment and retention of lymphocytes to the inflamed gut. The aim of this study was to investigate the possibility of imaging colitis radioimmunodetection by targeting the b 7 integrin with a radiolabeled antibody.
I nflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, is an immune-mediated intestinal inflammation affecting 0.5%-1% of the Western world's population. 1 This is a highly debilitating disease, which can have a severe impact on quality of life. As this is a chronic condition, treatment aims to keep it in remission by using antiinflammatory and immunosuppressant drugs, with surgery required for more serious cases. 2 Clinical diagnosis of the severity of intestinal inflammation is important but remains to be established. Imaging would provide more global information, which could improve therapy, but currently routine practice is limited to ultrasound, x-ray, computed tomography (CT), or magnetic resonance imaging (MRI), which lack specificity. Currently there are potentially a number of methods of imaging intestinal inflammation. 3, 4 Some are based on perturbations in metabolism and physiological effects, such as [ 18 F]FDG/ PET, which shows higher uptake in regions of tissue inflammation. However, there are a number of reasons why [ 18 F]FDG uptake can vary in the healthy bowel. 5, 6 Other techniques use single-photon radionuclide imaging to detect nonspecific antibody, or use autologous leukocytes, in both cases radiolabeled with either 99m Tc or 111 In. The labeled leukocytes concentrate in regions of inflammation and this method is often considered to be the gold standard for inflammatory imaging. This approach, however, requires that the technologists isolate the leukocytes, radiolabel them with 99m Tc or 111 In, and then reinject them, increasing the exposure of health workers to patient blood and also increasing the possibility that the blood cells will be contaminated during the labeling process. Antibodies raised against nonspecific cross-reactive antigen (NCA) and labeled with 99m Tc, 7 have also been investigated. Evaluation of the condition is often made through invasive techniques, such as colonoscopy, which can only assess part of the intestine, and therefore give an incomplete indication of the extent of disease. In addition, this is an evaluation which is operator-dependent and lacks objectivity. 8 An objective method for the detection and description of intestinal inflammation is clearly needed, and medical imaging, such as positron emission tomography (PET), is a potential way of solving this clinical problem.
Methods using labeled leukocytes focus on the basis of the pathology of this disease: chronic immune dysregulation is the primary cause of the inflammation and ulceration of the intestinal mucosa which form the pathology of the disease. This is mediated by the infiltration of leukocytes, and the b 7 -positive leukocyte subset therefore present as a favorable target for an imaging agent, being both populous and a functional indicator of the location and degree of inflammation. The b 7 integrin subunit is expressed on lymphocytes that have been activated in intestinal inductive sites, including Peyer's patches and mesenteric lymph nodes. 9 It is expressed as part of a heterodimeric integrin molecule in combination with either a 4 or a E , the 2 resulting heterodimers being involved in recruitment and retention of lymphocytes to the inflamed intestine, respectively. 10 The a 4 b 7 integrin binds to mucosal addressin cell-adhesion molecule-1 (MAdCAM-1), which is constitutively expressed on endothelial cells in the intestine. 10 The a E b 7 integrin is expressed by lymphocytes in mucosal epithelial sites and is involved in lymphocyte binding to E-cadherin, resulting in retention. The b 7 integrin represents a promising target for detection of colitis because of its specificity of expression by lymphocytes in this organ, being involved only in lymphocyte recruitment to the inflamed gut and not to other principal organs such as lung or liver. 11 Our aim in this study was to investigate whether the antibody FIB504.64 would have increased uptake in the intestines of mice with colitis. The antibody was radiolabeled with the positron-emitting radionuclide 64 Cu and injected into mice with experimental colitis induced by dextran sodium sulfate (DSS). [12] [13] [14] [15] Copper-64 was chosen because its half-life is commensurate with antibody pharmacokinetics. MicroPET imaging was used in combination with ex vivo tissue assay to measure radionuclide distribution in this acute model of colitis to investigate whether there was specific uptake in the inflamed gut.
MATERIALS AND METHODS

General
Chemicals and reagents were obtained from Sigma-Aldrich (St. Louis, MO) unless otherwise specified. EDC (1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide hydrochloride) was purchased from Pierce (Rockford, IL). S-2-(4-aminobenzyl)-1,4,7,10-tetraazacyclododocane tetraacetic acid (NH 2 -p-Bn-DOTA) was purchased from Macrocyclics (Dallas, TX). Metal-naive pipette tips were purchased from Rainin (Oakland, CA). Glass and plasticware were washed with 10% HNO 3 and rinsed thoroughly with ultrapure water (>15 MX resistivity) (Siemens, Lowell, MA) before use. Ultrapure water was also used in buffer preparation. Sodium acetate buffer (0.1 M, pH 5.0) was used for conjugation and radiolabeling. Metal contaminants in the buffer were decreased by passing through a Chelex-100 resin column (Bio-Rad Laboratories, Hercules, CA).
Antibody-chelator Conjugation
The anti-b 7 antibody was produced from its hybridoma (FIB504.64 16 ) and was purified using a HiTrap Protein G column (GE Healthcare, Piscataway, NJ). The control antibody was Rat IgG2a (BD Biosciences, San Jose, CA).
The antibody was buffer exchanged into sodium acetate (0.1 M, pH 5.0) and concentrated to %10 mg/mL using spin column filters (Centricon, Millipore, Bedford, MA) (MWCO 30 kDa). The bifunctional chelator NH 2 -p-Bn-DOTA was conjugated to the antibody using previously described methods. 17 Briefly, to NH 2 -p-Bn-DOTA in Me 2 SO (25 mg/mL) was added 3 volume equivalents of 0.1 M sodium acetate buffer (pH 5.0) to give a final bifunctional chelator concentration of %100 mg/mL. The pH was brought to 5.0 by addition of NaOH. The chelator was added to the antibody at a molar ratio of 250:1, followed by buffer, and then 500 molar equivalents of EDC, which was made up immediately before use in ultrapure water at a concentration of 50 mg/mL. The volume of reagents added diluted the antibody to a final concentration of 5 mg/mL. The reaction was gently mixed by pipetting, centrifuged to remove air bubbles, pH was confirmed to be 5.0, and then the reaction was placed in a 37 C water bath. The final concentration of Me 2 SO was always <5% (typically %1%). After 30 minutes unbound chelator was separated from the immunoconjugate by size exclusion highperformance liquid chromatography (HPLC) (BioSep SEC-S3000 column; Phenomenex, Torrance, CA) with an isocratic aqueous phase of 0.1 M sodium acetate, pH 5.0. Retention time of the immunoconjugate was typically 8.1 minutes, with the unbound chelator eluting at %11.0 minutes. Purified immunoconjugate fractions were pooled, concentrated, and then stored in aliquots at À80 C.
Immunoreactivity Assay
The immunoreactivity of the BFC-conjugated antibody was assayed by flow cytometry. 18 Briefly, 10 6 TK-1 cells (mouse T cells lymphoma) expressing a 4 b 7 integrin was stained with 10 lg/mL purified FIB504.64 or with the immunoconjugate for 30 minutes at 4 C. Then the cells were washed twice with FACS buffer (phosphate-buffered saline [PBS] þ 2% fetal calf serum) and counterstained with second mAb against rat IgG2a-Alexa 488 conjugate at 4 C for 30 minutes and subjected to flow cytometry (FACScan, BD Biosciences).
Isotope Dilution Assay
The ratio of protein molecules to available chelating molecules was measured using similar methods to those reported by Meares et al. 19 Typically, a solution of immunoconjugate of known concentration (%3 mg/mL) was prepared. A small amount of 64 Cu was added to a solution of cold copper prepared from a commercially available standard (Sigma Aldrich), the concentration of which was approximately twice the estimated concentration of available chelators on the antibody. This solution was vortexed, centrifuged, and left for at least 1 hour at room temperature. To 10 lL of NaOAc buffer in an Eppendorf microcentrifuge tube was added 10 lL of the cold copper/ 64 Cu mixture, followed by 10 lL of the antibody. The reaction was then mixed by pipetting and incubated at room temperature for at least 1 hour. Then 1 lL of the labeled protein was removed and added to 9 lL phosphate buffer (PB; 0.1 M, pH 8) containing 100 mM ethylenediamine-tetraacetic acid (EDTA). After 5 minutes 1 lL of the solution was spotted onto an ITLC plate (Instant Thin-Layer Chromatography Si Gel impregnated glass fiber sheets; Pall Life Sciences, Ann Arbor, MI), which was allowed to air-dry and then developed using PB (100 mM EDTA) as the mobile phase. The plate was cut into 4 sections and radioactivity in the sections was assayed using a gamma counter. Using these conditions, labeled antibody remains at the baseline of the plate with free copper moving with the solvent front. TLCs were also run of antibody incubated with no cold copper, 10 mM cold copper (to block all binding sites) and concentrations of copper lower than and higher than the target concentration. The number of available binding sites was calculated by the method reported. 19 
Radiolabeling
For imaging studies immunoconjugates were radiolabeled with 64 Cu as previously described. For example, to 2 mCi 64 Cu in 5-10 lL HCl (0.04 N) was added %3 volume equivalents of pH 5, 0.1 M acetate buffer. To this was added the antibody (e.g., 250 lg, 75 lL), also in acetate buffer. After 30 minutes of incubation at 25 C 1 lL of the reaction mixture was removed and added to 9 lL PB containing 100 mM EDTA. A TLC was run as before to assess radiolabeling (>95% required for injection). The radioimmunoconjugate was diluted with saline and sterile filtered (0.2 lm) before injection.
Experimental Colitis Model
DSS (36-50 kDa MW, from MP Biomedicals, Solon, OH), which is known to induce inflammation throughout the bowel, [12] [13] [14] [15] was included in the drinking water for 8 days at 2.0% (w/v).
Biodistribution Studies
Three groups of mice were involved in this study, 1 test group and 2 control groups: Group 1 (n ¼ 6) was treated with DSS and injected with the radiolabeled anti-b7 antibody; Group 2 (n ¼ 5) was not treated with DSS and was injected with the radiolabeled specific anti-b7 antibody; and Group 3 (n ¼ 5) was treated with DSS and injected with a 64 Cu-labeled nonspecific isotype-matched antibody (rat IgG 2a ). After 9 days of DSS treatment the radiolabeled antibody was injected into the tail vein of the mice (50 lg protein, 7.1 6 1.2 [mean 6 SD] MBq, 0.1 mL in saline). MicroPET images were collected for 30 minutes using a Siemens Focus 120 camera at 1, 24, and 48 hours postinjection. At 48 hours postinjection, microCT images were also collected using a Siemens MicroCAT II camera. After the microCT images were obtained the mice were euthanized by CO 2 inhalation and an ex vivo tissue biodistribution was carried out. Tissues were collected, weighed, and radioactivity was assayed using a Packard Cobra II automated gamma counter (Meriden, CT). Micro-PET and microCT images were registered manually using AMIDE software (A Medical Imaging Data Examiner, http://amide.sourceforge.net/index.html). Data from volumes of interest (VOIs) within relevant tissues were used to calculate biodistribution throughout the imaging study.
Statistical Analysis
Statistical analysis was carried out using SPSS v. 14.0 for Windows (Chicago, IL). The 48-hour postinjection ex vivo biodistribution data were analyzed for statistical significance by analysis of variance (ANOVA), with posthoc analysis adjusted using the Bonferroni correction. Differences were considered significant at the 5% level (P < 0.05).
RESULTS
DSS Model
Including DSS in the drinking water resulted in body weight loss, as is shown for treated and control groups in Figure 1 . The mean decrease in total body weight was 5.43 6 7.13% for treated mice; body weight gain for nontreated mice was 5.9 6 0.75% over the same period. In our experience this pattern of initial increase and then decrease in body weight is typical for mice treated with this level of DSS (2% w/v). 12 For all DSS-treated mice feces became more liquid during the course of the study and hemorrhage from the bowel was observed at necropsy.
Immunoreactivity Assay
In order to determine whether the conjugation of the chelator reduced the binding capacity of the anti-b 7 integrin mAb (FIB504.64) to its target, we examined the binding of FIB504.64 to TK-1 model cells. Flow cytometry data (Fig. 2) indicated that the immunoreactivity of the antibody was not impaired by the conjugation of the bifunctional chelator.
Isotope Dilution Assay and Antibody Radiolabeling
The number of chelators per protein was 1.06 6 0.14 for the nonspecific control antibody and 1.05 6 0.09 for FIB504.64 (mean of 3 separate determinations 6 SD). The antibodies labeled at specific activities of between 194:1 and 296:1 (MBq:mg) and radiochemical purity was always >95% before injection.
Blood Pharmacokinetics of the Radiolabeled Antibodies
At 1, 24, and 48 hours postinjection (p.i.), blood was taken by tail vein nick and radioactivity assayed. The results are presented in Figure 3 . As the inflamed intestine of Group 1 showed higher uptake of the specific antibody it could be that the lower blood radioactivity is due to sequestration in the gut of Group 1, while in Group 3 the nonspecific antibody had no target organ or tissue, resulting in a longer blood half-life. There was a statistical difference (P < 0.05) in the radioactivity in the blood between groups 1 (test group) and 3 (control group, nonspecific antibody, DSS-treated mice) at both 24 and 48 hours with activity in Group 1 lower at both timepoints (Group 1; 12.93 6 2.12 percentage of injected dose per gram of tissue [%ID/g], 7.29 6 3.29 %ID/g: group 2; 20.63 6 3.69, . Blood pharmacokinetics of radiolabeled antibodies in DSS-induced colitis mice. Pharmacokinetics (percentage of injected dose per gram of tissue, %ID/g) of radiolabeled antibodies in mouse blood at 1, 24, and 48 hours postinjection. Diamonds ¼ Group 1 (test), squares ¼ Group 2 (control, specific antibody, no colitis), triangles ¼ Group 3 (control, nonspecific antibody, colitis). The antibody cleared from the blood pool in a typical pattern for a whole antibody. Lower levels of radiolabeled antibody in the blood of the test group could be due to sequestration in the inflamed gut. The decay corrected data presented are the means 6 SD for n ¼ 5-6.
12.62 6 1.33: means 6 SD at 24 and 48 hours, respectively).
MicroPET Imaging
Representative microPET images are shown in Figure  4 . The distribution of radionuclide at 1, 24, and 48 hours p.i. in DSS-treated mice injected with the 64 Cu-labeled anti-b 7 antibody are shown in Figure 4A(1-3) . The images show that the radiolabeled antibody was initially (at 1 hour p.i.) distributed throughout the blood pool with some activity in the bladder, that by 24 hours p.i. there was some specific uptake in the target area, and that by 48 hours p.i. the radionuclide was clearing from the blood and that there was specific uptake in the gut. For comparison, microPET/ microCT images of radionuclide distributions in control mice at 48 hours p.i. (Fig. 4B,C) show similar radionuclide levels in the normal organs but much lower levels in gut for non-DSS-treated mice injected with the radiolabeled specific antibody (Fig. 4B) , and for DSS-treated mice injected with radiolabeled isotype-matched nonspecific antibody (Fig. 4C) .
Values from VOIs drawn around organs were converted to %ID/g 6 estimate standard deviation (ESD) and are presented as bar graphs in Figure 5 . Patterns of clearance from nontarget tissues are typical for a radiolabeled antibody. High initial uptake in the liver shows evidence of clearing by 48 hours, as does radioactivity in the kidney. Radioactivity is clearing more rapidly from the lung following blood clearance. Muscle and brain have very low levels of radionuclide, which clear from these tissues throughout the study. Radioactivity levels in the gut were relatively stable throughout the time course studied for all groups. While there was higher uptake of antibody in the gut in Group 1 (5.47 6 2.0), it was not as different from the other groups as in the ex vivo dissection biodistribution (%ID/g 6 ESD by image analysis in the gut for Group 2 was 4.44 6 1.2, for Group 3 was 4.24 6 0.14). This reflects the difficulty in identifying large intestine in the image. These data are also not a fair reflection of the variation of antibody uptake within the gut. As can be seen in Figure 4 , there are a number of hot spots of high uptake of radionuclide in the gut of Group 1 which are not seen in the other groups. For example, the 90th percentile values of the gut VOIs from the individuals in the images for Groups 1, 2, and 3 were 14.23 %ID/g, 5.02 %ID/g, and 7.48 %ID/g, respectively. To represent the range of counts in the gut VOIs the %ID/g for each voxel was calculated for a mouse from each of the three groups. These data are presented in Figure 5 as line graphs. It can be seen that the count distributions for control Groups 2 and 3 follow an approximation to a normal distribution about the mean at all timepoints. However, the graphs for Group 1 have a much more heterogeneous distribution with much higher maximal uptake values due to these hot spots. This is evident at both 24 and 48 hours p.i.
Ex Vivo Biodistribution Assay
The results of the 48-hour p.i. ex vivo biodistribution assay and the results from statistical analysis of these data are given in Table 1 . Uptake in the large intestine was higher for the test group than for the controls, achieving statistical significance between Groups 1 and 2 (%ID/g in large intestine: Group 1 ¼ 6.49, Group 2 ¼ 3.64, Group 3 ¼ 3.97). The lack of differential between the groups for stomach and small intestine is surprising, as DSS causes inflammation throughout the digestive tract. However, it has been reported that DSS has a greater effect on the large intestine than the rest of the gut. 13 The lower amount of radioactivity in blood, heart, lung, and kidney for Group 1 compared with the other 2 groups might have been due to sequestration in the large intestine. The differences in antibody uptake in liver and spleen could have a biological basis rather than be due to clearance because the specific antibody had higher uptake in these organs in control mice compared with DSS-treated mice, and also uptake of nonspecific antibody in DSStreated mice was lower in these organs (%ID/g for liver:
Group 1 ¼ 8.48, Group 2 ¼ 11.57, Group 3 ¼ 6.72). Uptake of the specific antibody in liver in DSS-treated mice might have been restricted by uptake in the target organ.
DISCUSSION
The development of an imaging agent specific for colonic inflammation would aid in its diagnosis, assessment, and in evaluating response to therapy. It is important to have a measure of not only the existence, but also the degree of disease. The presence of white blood cells is a reliable indicator of inflammation, although infection also has to be taken into account. In this study we report the biodistribution of antibody FIB504.64 that binds to the integrin b 7 , which is expressed mainly on gut lymphocytes. This integrin, in combination with integrins a 4 and a E , plays a role in the recruitment to and retention of lymphocytes in the intestine. Higher uptake of the radiolabeled antibody in the intestine of mice with acute colitis compared with controls was found by both microPET imaging and ex vivo tissue assay, suggesting that the b 7 integrin monomer could be a viable target for colitis imaging and that the radiolabeled antibody, targeting a subset of lymphocytes, could serve as a specific imaging agent. It is difficult to comment on which integrin heterodimer, a 4 b 7 or FIGURE 5. Analysis of biodistribution data obtained from microPET. Biodistribution data obtained from microPET images. Data obtained at 1 hour (black), 24 hours (gray), and 48 hours (white) postinjection of radiolabeled antibody. VOIs were drawn around organs and the counts were converted to %ID/g (6ESD). High uptake was found in the liver and kidneys. Radionuclide cleared from the lung following blood clearance and was low in muscle and brain. A VOI was drawn around the gut resulting in averaging of high and low regions of uptake. Radioactivity concentration-frequency line graphs for VOIs for the gut regions of individuals at 1 hour (dotted line), 24 hours (dashed line), and 48 hours postinjection are presented, which give a better representation of foci of high uptake in the test group compared with controls. a E b7, is the major target for this antibody in vivo. This could be investigated in future work comparing, for example, the biodistribution data obtained in this study (FIB504.64) and DATK32 which binds to a 4 b 7 . 16 Previous work in developing imaging agents for nuclear medicine has focused on the distribution of white blood cells (lymphocytes, macrophages, and neutrophils), which have been detected through either ex vivo or in vivo radiolabeling. There has been an almost chronological increase in the specificity of agents used for inflammation imaging. Gallium-67 concentrates at sites of infection, possibly through more than 1 mechanism: uptake of the metal into circulating leukocytes which then concentrate at the infected area, by the infectious agents themselves via siderophores, or by concentration at the site of infection by binding to lactoferrin excreted by leukocytes, might all play a role. 20 Nonspecific radiolabeled IgG also shows uptake in inflamed tissue, with the Fc region being necessary for concentration. 21 Liposomes have also been used for inflammation imaging, concentration in inflamed tissues being due to nonspecific uptake. 22 More targeted methods focus on imaging lymphocytes by either autologous reintroduction of radiolabeled leukocytes, or through in vivo labeling methods, such as the injection of an antibody that binds to granulocytes. The murine IgG1 antigranulocyte antibody BW250/183 binds to the nonspecific crossreacting antigen (NCA-95) which is expressed on granulocytes, 23 but it is also expressed on normal gut mucosa, challenging specificity of the technique. 24 In a comparison of nonspecific IgG, liposomes, and granulocytes it was found that all visualized colonic inflammation within 1 hour. 25 Neutrophil binding 99m Tc-labeled IL-8 was found to give similar uptake in inflamed gut as 99m Tc-HMPAO-labeled leukocytes at 1 hour, but radiolabeled IL-8 uptake continued to increase in diseased gut up to 4 hours, enabling better discrimination of inflamed regions of tissue. 26 Kanwar et al 27 reported that localization of 111 In-labeled anti-CD4 þ antibody to DSS-inflamed gut correlated well with pathology. More closely related to this work is the use of anti-MAd-CAM-1 antibody (MECA-367) to functionalize microbubbles for ultrasound detection of colitis. 28 Again, there was a strong correlation between uptake and pathological inflammatory scores.
Targeting leukocytes does have some disadvantages. For example, they can make their way through the diseased bowel wall and into the stool, so regions of bowel distal to the disease site are visualized, depending on when the imaging takes place in relation to the injection of radiolabeled material. Serial imaging can overcome this obstacle, as can use of a high-resolution imaging technique, such as PET, in order to discriminate intraluminal residence of the radionuclide from that in the intestine. Uptake at the target site will have been raised by the increased permeability at sites of inflammation, although this might also have increased nonspecific accumulation of radiolabeled antibody. The presence of macrophages at Higher uptake of radiolabeled anti-b 7 integrin monomer antibody FIB504.64 was detected in the large intestine of mice treated with DSS compared with control groups 2 and 3. Data are percentage injected dose per gram (%ID/g) (mean 6 SD). Statistical differences of P < 0.05 are highlighted in bold. The Bonferroni correction was used for post-hoc analysis.
sites of colonic inflammation might also increase nonspecific accumulation of this whole antibody through interaction with the Fcc receptors of invading neutrophils and macrophages.
It is relevant to note that antibodies binding to these molecules can be employed therapeutically. Patients treated with anti-a 4 b 7 antibody (MLN02) had a higher probability of clinical remission within 6 weeks than a placebo-treated control group (P ¼ 0.03). 29 This might have relevance to this study because 50 lg of radiolabeled antibody was given to each mouse, which for a 25 g mouse means that the antibody was given at 2.0 mg/kg, which was the highest level given to the patients with therapeutic effect. Therefore, the radiolabeled antibody could have effected the lymphocyte trafficking. Future studies could investigate the effects of varying the amounts of administered antibody on the imaging and distribution data.
In this study an acute experimental murine model of colitis was employed. As with all animal models, this model has advantages and potential shortfalls. It has been reported that DSS can bind directly to the b 7 integrin. 30 This could have perturbed the study in 2 ways: antibody binding of b 7 could have been decreased through physical blocking by DSS; or expression of b 7 by the lymphocytes could have been upregulated to compensate for DSS binding. In future studies other models will be investigated which do not involve DSS and are more relevant to the chronic clinical situation. For example, adoptive T transfer is a more chronic model simulating the prolonged inflammation typical of Crohn's disease and ulcerative colitis, 31 and T-bet deficient mice that spontaneously develop colitis would be more similar to ulcerative colitis disease. 32 Data have so far been collected at the macro scale, but to fully understand the images obtained higher resolution data are needed. Therefore, autoradiography will also be employed to study the localization of radionuclide in relation to histopathologically demonstrated tissue inflammation, Peyer's patches, mesenteric lymph nodes, and other relevant tissues.
CONCLUSION
In this report we describe the radiolabeling of an anti-b 7 integrin antibody and its use in detecting acute colitis in an experimental murine model using microPET. Use of b 7 monomer as a target for colitis imaging not only identifies a new target, but also introduces a more specific level of inflammation targeting. The lymphocytes expressing b 7 are not only in regions of inflamed gut, but they have been locally activated as a result of the inflammation.
Further work in this area will focus on 2 main areas. First, the molecular properties of the targeting agent will be manipulated to improve its characteristics as an imaging agent by, for example, reducing its molecular weight which will shorten its blood half-life and accelerate clearance from nontarget organs. Second, the targeting ability of the antibody will be employed to develop specific delivery systems for therapy of the colonic inflammation. 18 
